Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Clayton

Showing results (291-300 of 294) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 294 results.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamidesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.
JAMA|December 9, 2024
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical TrialPaul Dark, Anower Hossain, Daniel F McAuley, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonistsMichael R Wood, Kathy M Schirripa, June J Kim, et al.
Journal of Medicinal Chemistry|February 7, 2003
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridinesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.
Pageof 30

Showing results (291-300 of 294) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 294 results.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamidesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.
JAMA|December 9, 2024
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical TrialPaul Dark, Anower Hossain, Daniel F McAuley, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Alpha-hydroxy amides as a novel class of bradykinin B1 selective antagonistsMichael R Wood, Kathy M Schirripa, June J Kim, et al.
Journal of Medicinal Chemistry|February 7, 2003
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridinesChristopher S Burgey, Kyle A Robinson, Terry A Lyle, et al.
Pageof 30